Zoledronate T29581+


Indications and Reactions:

Role Indications Reactions
Primary
Metastases To Bone 25.0%
Breast Cancer 18.0%
Multiple Myeloma 16.0%
Prophylaxis 7.7%
Cancer Pain 5.0%
Breast Cancer Female 4.7%
Resorption Bone Increased 4.3%
Bone Disorder 3.7%
Prostate Cancer 3.7%
Bone Density Decreased 2.7%
Hypertension 2.3%
Metastatic Renal Cell Carcinoma 1.3%
Osteoporosis 1.0%
Pain 1.0%
Blood Cholesterol 0.7%
Cholangitis 0.7%
Herpes Zoster 0.7%
Liver Disorder 0.7%
Pancreatic Carcinoma 0.7%
Antacid Therapy 0.3%
Death 23.7%
Malignant Neoplasm Progression 14.0%
Osteonecrosis Of Jaw 6.5%
Respiratory Failure 6.5%
Pyrexia 5.4%
Hypocalcaemia 4.3%
Pneumonia 4.3%
Tooth Extraction 4.3%
Osteonecrosis 3.2%
Peripheral Sensory Neuropathy 3.2%
Prostate Cancer 3.2%
Toothache 3.2%
Weight Decreased 3.2%
Dyspnoea 2.2%
Gingival Bleeding 2.2%
Multiple Myeloma 2.2%
Osteomyelitis 2.2%
Pleural Effusion 2.2%
Pneumonia Aspiration 2.2%
Prostatic Specific Antigen Increased 2.2%
Secondary
Breast Cancer Female 33.1%
Breast Cancer 15.7%
Metastases To Bone 14.2%
Multiple Myeloma 13.4%
Bone Density Decreased 6.3%
Cancer Pain 6.3%
Colorectal Cancer Metastatic 3.1%
Resorption Bone Increased 3.1%
Prophylaxis 2.4%
Bone Lesion 0.8%
Lung Neoplasm Malignant 0.8%
Prostate Cancer 0.8%
White Blood Cell Count Decreased 17.6%
Vaginal Infection 8.8%
Death 5.9%
Malignant Neoplasm Progression 5.9%
Metastases To Spine 5.9%
Prostate Cancer 5.9%
Septic Shock 5.9%
Skin Toxicity 5.9%
Thrombocytopenia 5.9%
Toothache 5.9%
Vomiting 5.9%
Breast Cancer 2.9%
Malignant Ascites 2.9%
Multiple Myeloma 2.9%
Osteochondrosis 2.9%
Pain 2.9%
Peripheral Sensory Neuropathy 2.9%
Tooth Extraction 2.9%

Drug Data